Doctors fret about long-term impact of expensive drugs

The New York Times looks at the growing number of biotech drugs that cost as much as $10,000 per month, often only prolonging patients' lives by a matter of weeks or months. For some cancer specialists, it seems only a matter of time before the use of the super-expensive drugs is rationed. And analysts note that pressure will grow as hundreds of late-stage biotech drugs are approved by the FDA.

- read this article from The New York Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.